NCT05465252 Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression
| NCT ID | NCT05465252 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Condition | Age-Related Macular Degeneration |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-10-17 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2025-10-17 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized, double-blind, placebo-controlled study aims to evaluate the effect of krill oil supplementation in patients with dry age-related macular degeneration (AMD). Participants will receive 4 capsules of krill oil or placebo daily for a period of 3 months. Outcomes will be evaluated after 3-month treatment to assess differences between the two study groups.
Eligibility Criteria
Inclusion Criteria: * Adults diagnosed with dry AMD at an early or intermediate stage, classified according to the Beckman Classification and confirmed by fundus photography: (1) Early AMD: medium drusen (\>63 μm and ≤125 μm) without AMD-related pigmentary abnormalities; (2) Intermediate AMD: large drusen (\>125 μm), with or without AMD-related pigmentary abnormalities. * Willing to stop supplementation of omega-3 fatty acids, choline, or astaxanthin. * Willing to sign the informed consent, and willing to attend follow-up visits for at least 3 months. Exclusion Criteria: * Any eye with disease that would interfere with the fundus examinations. * Eye with choroidal neovascularization (CNV), geographic atrophy (GA), or high myopia. * Surgeries that may interfere with AMD evaluation. * Long-term use of any medications that are associated with retinal or neural toxicities. * History of supplementation with lutein, zeaxanthin, DHA, or EPA, unless a wash-out period of at least 8 weeks is completed prior to enrollment. * Intraocular pressure more than 26 mmHg. * Received cataract surgery in 3 months. * Other conditions: subjects with severe systemic diseases; any condition that causes high risk of drop-out, or low compliance, for instance cognition disorder; have been involved in other trial that interfere with the current visit plan; taking other angiogenesis Inhibitors drugs for treating cancer. * Other conditions not suitable for the current study.
Contact & Investigator
Xiaodong Sun, PHD
PRINCIPAL INVESTIGATOR
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Frequently Asked Questions
Who can join the NCT05465252 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 85 Years, studying Age-Related Macular Degeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05465252 currently recruiting?
Yes, NCT05465252 is actively recruiting participants. Contact the research team at jiahuixun@163.com for enrollment information.
Where is the NCT05465252 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT05465252 clinical trial?
NCT05465252 is sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. The principal investigator is Xiaodong Sun, PHD at Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. The trial plans to enroll 24 participants.